Results 1 to 10 of about 27,163 (253)
Fingolimod modulates microglial activation to augment markers of remyelination [PDF]
, 2011 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work ...
Baker, D, Giovannoni, G, Jackson, SJ
core +5 more sources
Beneficial effects of fingolimod in MS patients with high serum Sema4A levels. [PDF]
PLoS ONE, 2018 We previously demonstrated that patients with multiple sclerosis (MS) of high serum Sema4A levels are resistant to IFN-β therapy. To further elucidate the role of serum Sema4A as a biomarker for therapeutic stratification in MS patients, it is important ...
Toru Koda +13 more
doaj +3 more sources
Novel Finding of Retinal Aneurysmal Alterations in Patients Undergoing Fingolimod Therapy for Multiple Sclerosis [PDF]
Neurology and TherapyIntroduction Fingolimod (Gilenya®), commonly used for relapsing-remitting multiple sclerosis (RRMS), is the first approved oral immunomodulatory agent.
Feliciana Menna +5 more
doaj +2 more sources
Fingolimod phosphate protection against mitochondrial damage in neuronal cells [PDF]
, 2019 Background: Major role of oxidative stress in the pathogenesis of neurodegenerative diseases have been suggested, being mitochondria one of the main sources of ROS. Aim: In the present work, we have studied the antioxidant effect of fingolimod phosphate
Alvarez-Gil, Antonio +8 more
core +3 more sources
Fingolimod as a potent anti-Staphylococcus aureus: pH-dependent cell envelope damage and eradication of biofilms/persisters [PDF]
BMC MicrobiologyBackground The urgent need for new antibacterial drugs has driven interest in repurposing therapies to combat Gram-positive biofilms and persisters.
Yongpeng Shang +5 more
doaj +2 more sources
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis [PDF]
New England Journal of Medicine, 2010 Jeffrey A Cohen +2 more
exaly +2 more sources
Fingolimod and Diabetic Retinopathy: A Drug Repurposing Study
Frontiers in Pharmacology, 2021 This study aimed to investigate the interactions between fingolimod, a sphingosine 1-phosphate receptor (S1PR) agonist, and melanocortin receptors 1 and 5 (MCR1, MCR5).
Carlo Gesualdo +17 more
doaj +1 more source
Applied Sciences, 2022 Fingolimod is a sphingosine 1-phosphate-receptor modulator approved for the oral treatment of relapsing–remitting multiple sclerosis (RRMS), a form of MS characterized by a pattern of exacerbation of neurological symptoms followed by recovery.
Claudia Fracasso +6 more
doaj +1 more source
Fingolimod increases parvalbumin-positive neurons in adult mice
IBRO Neuroscience Reports, 2022 In recent years, it has been shown that central nervous system agents, such as antidepressants and antiepileptic drugs, reopen a critical period in mature animals.
Hiroshi Ueno +6 more
doaj +1 more source